The team of SeqBiome CTO, Prof Paul Cotter, have continued to be very active in recent months publishing multiple papers relating to food chain, food, animal and human microbiomes. This includes the monitoring of the microbiomes foods (here, here and here), food processing facilities, porcine, vaginal, and lung microbiomes, as well as the impact of diet on human gut microbiomes (here and here).
The use of Machine Learning (ML) carries enormous potential, but also challenges, for making the most out of microbiome studies. SeqBiome CEO is also Chair of the EU COST Action ML4Microbiome who recently published two reviews in Frontiers in Microbiology on the current state-of-the-art of ML in microbiome research, read more here and here.
As the only Irish participant, SeqBiome is one of 10 start-ups selected from over 200 applicants to partake in the prestigious PepsiCo’s Greenhouse Accelerator program.
The program, which is now in its fifth year, seeks to support the acceleration of ingredients, products or services that encourage a healthy lifestyle and enable health management and wellness on a global scale.
This accelerator program will help SeqBiome to develop our microbiome expertise into a competitive offering to both professional and amateur health, as well as sports-focused consumers, to improve or maintain their physical and mental performance
Read more in the Forbes.
SeqBiome CTO and co-founder Prof Paul Cotter leads the Irish Coronavirus Sequencing Consortium, see here for more details. There is also an interview in the Irish Examiner about the consortium and Paul also provided an overview of the consortium for RTE’s ‘10Things to Know About’ programme.
Paul Cotter, SeqBiome CTO, was one of the 33 Ireland-based researchers to be named on Clarivate’s 2020 list of Highly Cited researchers. This is the third consecutive year that Paul was included on this list.
SeqBiome Ltd. is today launched after spinning out from APC Microbiome Ireland, SFI Research Centre, University College Cork and Teagasc (the Irish Agriculture and Food Development Authority).
SeqBiome provides high-quality and interactive sequencing and microbiome analysis for academia and industry. The offering is comprehensive and spans the microbiome project continuum with an aim of creating meaningful microbiome insights for clients across industries such as Pharmaceuticals, Nutrition, Sport, Healthcare, Agriculture and other Life Sciences.
SeqBiome CEO and co-founder Dr Marcus Claesson publish two large microbiome studies on inflammatory bowel disease in Nature Communications and Gut.
Read more in NutraIngredients.